Patent application title: Thrombin Generation Determination Method
Enriqueta Coll (Orlando, FL, US)
Ali Amirkosravi (Longwood, FL, US)
John Francis (Longwood, FL, US)
Adventist Health System/Sunbelt, Inc.
IPC8 Class: AC12Q137FI
Class name: Measuring or testing process involving enzymes or micro-organisms; composition or test strip therefore; processes of forming such composition or test strip involving hydrolase involving peptidase
Publication date: 2011-07-28
Patent application number: 20110183365
A method for measuring a generation of thrombin in a sample of whole
blood as a function of time includes adding to a sample of whole blood a
fluorogenic substrate and a thrombin activator to form an activated
sample. A conversion product is permitted to form in the activated
sample. Fluorescence is measured as a function of time from a fluorescent
group that is released during the formation of the conversion product
with the use of a fluorescence detector. The fluorescence detector
operates in an extended range mode and has an increased sensitivity.
Thrombin generation as a function of time can then be calculated from the
measured fluorescence as a function of time.
1. A method for measuring a generation of thrombin in a sample of whole
blood as a function of time comprising: to a sample of whole blood adding
a fluorogenic substrate and a thrombin activator to form an activated
sample; permitting a conversion product to form in the activated sample;
measuring fluorescence as a function of time from a fluorescent group
released during the formation of the conversion product with the use of a
fluorescence detector operating in an extended range mode and having an
increased sensitivity; and calculating thrombin generation as a function
of time from the measured fluorescence as a function of time.
2. The method recited in claim 1, wherein the fluorescence detector is used with a filter set comprising 360.+-.40 nm excitation and 460.+-.40 nm emission range.
3. The method recited in claim 1, wherein the fluorescence is measured at a rate of once per 30 sec for 60 min at 37.degree. C.
4. The method recited in claim 1, wherein the increased sensitivity comprises an increase from 42 units to 70 units.
5. The method recited in claim 1, wherein the extended range mode comprises extending a range from 0 to 99,999 to 0 to 5,800,000 units.
6. The method recited in claim 1, further comprising preparing an assay calibrator comprising a mixture of heat-inactivated platelet-poor plasma and autologous washed red blood cells, the mixture comprising a heat-inactivated whole blood and having a hematocrit substantially the same as a hematocrit of the whole blood sample.
7. The method recited in claim 1, wherein the whole blood sample comprises whole blood plus HEPES buffer containing bovine serum albumin in a proportion of approximately 4:1.
8. The method recited in claim 1, wherein the thrombin activator comprises calcium chloride.
BACKGROUND OF THE INVENTION
 1. Field of the Invention
 The present invention relates to blood assays, and, more particularly, to methods for assaying thrombin generation, and, most particularly, to methods for assaying thrombin generation in a whole blood sample.
 2. Description of Related Art
 The coagulation of blood occurs through a complex series of reactions that function as a biological amplifier and culminate in the conversion of soluble circulating fibrinogen into a fibrin meshwork at the site of a vascular injury, providing stability to a hemostatic plug of platelets. In this system, relatively few initiating substances sequentially and proteolytically activate a cascade of circulating precursor proteins, the coagulation factor enzymes.
 Among the reactions is the conversion of prothrombin to thrombin, which is the pivotal enzyme of the coagulation system. Thrombin is a serine protease that rapidly activates platelets and converts fibrinogen to insoluble fibrin. Thrombin also converts FXIII to FXIIIa, which chemically cross-links the fibrin clot.
 Abnormalities in the coagulation cascade can have potentially fatal effects, leading to extremes of bleeding disorders and excessive clotting, thrombosis.
 It is known to assess the coagulation system by activating the cascade and measuring the time it takes for the sample blood or plasma to clot. Although clotting times provide clinically useful information, they actually only represent the initial (<5%) thrombin generation. The majority of thrombin is formed after this initial period.
 Attempts have been made to quantify the dynamics of thrombin formation. Hemker et al. have devised a commonly used technique ("Thrombin Generation in Plasma: Its Assessment via the Endogenous Thrombin Potential," Thrombosis and Haemostasis 74, 134-38, 1995; "Continuous Registration of Thrombin Generation in Plasma, Its Use for the Determination of the Thrombin Potential, Thrombosis and Haemostatis 70, 617-24, 1993; "The Thrombogram: Monitoring Thrombin Generation in Platelet Rich Plasma," Thrombosis and Haemostasis 83, 589-91, 2000; "Calibrated Automated Thrombin Generation Measurement in Clotting Plasma," Pathophysiology Haemostasis and Thrombosis 33, 4-15, 2003; the contents of all of which are incorporated hereinto by reference).
 The techniques of Hemker et al. include the addition of a thrombin activator to a plasma sample together with a fluorogenic thrombin substrate. Thrombin formed during the clotting reaction consumes the substrate, producing a conversion product that is detected fluorometrically in real time. From these data can be calculated the endogenous thrombin potential (ETP), which indicates how much thrombin has been active and for how long. The data can also be used to calculate a lag time (the time to formation of thrombin), the maximal thrombin concentration reached, and the time to the peak thrombin formation.
 What has not been successfully achieved, however, is the measurement of thrombin generation in whole blood, primarily owing to fluorescence signal quenching by red blood cells.
SUMMARY OF THE INVENTION
 The present invention is directed to a method for measuring a generation of thrombin in a sample of whole blood as a function of time. The method comprises adding to a sample of whole blood a fluorogenic substrate and a thrombin activator to form an activated sample. A conversion product is permitted to form in the activated sample. Fluorescence is measured as a function of time from a fluorescent group that is released during the formation of the conversion product with the use of a fluorescence detector. The fluorescence detector operates in an extended range mode and has an increased sensitivity. Thrombin generation as a function of time can then be calculated from the measured fluorescence as a function of time.
 Thrombin is the pivotal molecule in the coagulation process, and is generated through the cooperation of plasma proteins and blood cells. The importance of platelets in the coagulation process is also well established, as is that of white blood cells. While red blood cells are less active, in a small percentage of them, the outer membrane exhibits procoagulant ability.
 It is therefore believed that it is preferable to use whole blood rather than plasma to evaluate the overall thrombin generation capacity of blood, with all the cellular and plasmatic components (i.e., platelets, monocytes, and coagulation and fibrinolytic plasma proteins) in their natural environment. The present invention allows the calculation of the time course of thrombin activity in whole blood as a complete entity under controlled conditions, providing a measure of the amount of active thrombin that is present in the blood during the clotting process. The present assay therefore provides a reliable measurement method for hemostasis and thrombosis studies.
 A major problem associated with studying thrombin generation in whole blood has been the quenching of fluorescence by red blood cells. The present invention solves this problem by capturing the fluorescence signals that are stable and consistent, and follow typical performance characteristics of thrombin generation assays, allowing the calculation of all thrombin generation parameters.
 The present method is also advantageous as it enables the measurement of thrombin generation in a whole blood sample that is minimally manipulated and diluted. Several samples can be assayed at the same time using 5 replicates and 2 calibrator wells. The type and amount of synthetic fluorogenic thrombin substrate added to the sample is substantially exactly the same as for the plasma samples (e.g., Z-Gly-Gly-Arg-AMC). No additional devices are needed beyond a fluorescent plate reader having a high sensitivity photomultiplier and the capacity to extend the reading range.
 The present method can be used to evaluate hypo- and hyper-coagulable conditions. As thrombotic diseases, such as coronary infarction, stroke, pulmonary embolism, etc., are responsible for approximately one-half of death and disability in Western society, the present method can be useful for evaluating the pro-thrombotic capacity of a patient. The method can also therefore provide valuable research data in comparing coagulability data between patient groups, following treatment protocols and results, studying drug benefits in reducing thrombin generation of the blood, and developing improved assays and apparatus for coagulation measurement.
BRIEF DESCRIPTION OF THE DRAWINGS
 FIG. 1 is a flowchart of an exemplary method of the present invention.
 FIG. 2 is a fluorescence trace over time obtained on a sample from a single donor.
 FIG. 3 is a graph of thrombin concentration as a function of time for a single donor at different hematocrits (--, 33%; - -, 37%; Δ, 40%; ∘, 44%; and quadrature, 54%).
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
 A description of the preferred embodiments of the present invention will now be presented with reference to FIGS. 1-3.
 The method 100 (FIG. 1) of the present invention includes preparing an assay calibrator (block 101) by mixing heat-inactivated platelet-poor plasma and autologous washed red blood cells in PBS without calcium and magnesium to obtain "heat-inactivated whole blood," having substantially the same hematocrit as the original blood sample. Thrombin (20 μl) is then added to the assay calibrator (block 102).
 A whole blood sample is prepared that comprises whole blood (WB) plus BBSA6 (HEPES buffer containing 6 g/l BSA) in a proportion of approximately 4:1 (e.g., 80 μl and 20 μl, respectively). The sample is prepared in quintuplicate in 96-well microtiter plates (block 103). Each sample has its own calibrator, comprising 20 μl thrombin and 80 μl WB calibrator in duplicate.
 The plate is inserted into a fluorometer (block 104), for example, a Synergy 2 Multi-Mode Microplate Reader fluorometer (BioTek Instruments, Inc., Winooski, Vt.) equipped with a filter set comprising a 360±40 nm excitation and 460±40 nm emission range and a dispenser, although this particular device is not intended as a limitation. The fluorometer will have been altered so as to read in extended range mode, increasing the range from a standard range of 0-99,999 to an extended range of 0-580,000 units. The sensitivity will also have been substantially increased, for example, from 42 units to 70 units. Further, the parameters of the fluorometer will have been adjusted to read emitted fluorescence from the bottom of the plate.
 Thrombin generation is substantially immediately triggered by adding 20 μl of a fluorogenic substrate/calcium chloride solution (block 105). The fluorogenic substrate can comprise, for example, Z-GGR-AMC (Bachem, Switzerland) dissolved to a concentration of 5 mM in a buffer containing 10% DMSO, although this is not intended as a limitation. The buffer can comprise, for example, 20 mM HEPES, 150 mM NaCl, and 60 mg/ml bovine serum albumin (BSA, Sigma).
 As known in the art, the reaction includes the cleaving off of a fluorescent group that is then detected by the fluorometer, and a conversion product is formed (block 106). Fluorescence is measured over time, for example, once per 30 sec over 60 min, at 37° C. (block 107), using the adapted fluorometer as described above.
 The kinetic data collected are exported to a software package, for example, Microsoft® Excel®, for processing. Among the parameters that can be measured are included thrombin generation parameters such as lag time (min), time to peak (min), peak thrombin concentration (nmol/l), velocity index (nM/min), and endogenous thrombin potential (ETP, nmol/l-min) (block 108), in ways known in the art. Briefly, the fluorescence signal is converted to thrombin concentration by continuous comparison with the signal generated by the thrombin calibrator after compensating for thrombin decay, variability in light absorption, substrate consumption, and inner filter effect, and adjusted for the α2-macroglobulin-thrombin complex activity present in the sample.
 This method 100 can also be adapted to other embodiments, such as adding activators (tissue factor, phospholipids), induction of tissue factor expression (e.g., bacterial endotoxin), or inhibitors (e.g., corn trypsin inhibitor, CTI). The current method 100 does not require the addition of exogenous tissue factor (TF) or phospholipids to obtain data for the calculation of TGA parameters; however, if the thrombin generated is very low, TF can be added to the sample to trigger the reaction. Other reagents such as endotoxin or CTI can be included to explore clotting activation by different pathways.
 The present method 100 has been used to obtain the following data. FIG. 2 is a fluorescence trace over time obtained on a sample from a single donor. FIG. 3 is a series of thrombin concentration graphs as a function of time for a single donor at different hematocrits. Different hematocrits were obtained after sedimentation of the red blood cells by centrifugation and re-suspension (after wash in PBS) in platelet-poor plasma, using specific volumes to obtain the desired variable hematocrits.
 Having now described the invention, the construction, the operation and use of preferred embodiments thereof, and the advantageous new and useful results obtained thereby, the new and useful constructions, and reasonable mechanical equivalents thereof obvious to those skilled in the art, are set forth in the appended claims.
Patent applications by Ali Amirkosravi, Longwood, FL US
Patent applications by Enriqueta Coll, Orlando, FL US
Patent applications by John Francis, Longwood, FL US
Patent applications by Adventist Health System/Sunbelt, Inc.
Patent applications in class Involving peptidase
Patent applications in all subclasses Involving peptidase